abemaciclib tablets
Food and Drug Administration approved abemaciclib (Verzenio,Eli Lilly and Company)with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of adult patients with hormone receptor (HR)-positive
Are you looking for or in search of FDA approved “abemaciclib tablets in India”? “Medicant Healthcare” a registered pharmacy firm in India deals in both brand name as well as generic name Drugs / medicine approved for Breast Cancer. Need Access of abemaciclib tablets, get in touch with our healthcare professional.
abemaciclib tablets
These drugs are approved for women with advanced hormone receptor-positive, HER2-negative breast cancer and are taken as pills, typically once or twice a day.
There are different ways to use these drugs.
- Any of the three drugs can be given along with an aromatase inhibitor (AI) or fulvestrant to women who have gone through menopause.
- Any of these three drugs can also be given with fulvestrant or an aromatase inhibitor to women who are still having regular periods (premenopausal) or are almost in menopause (perimenopausal). These women, however, must also be on medicines, such as luteinizing hormone-releasing hormone (LHRH) analogs, that stop the ovaries from making estrogen or have their ovaries removed with surgery.
- Abemaciclib can also be used by itself in women who have previously been treated with hormone therapy and chemotherapy.
Contact Medicant Healthcare
Products
Contact No.
Call us
+91 11 4350 7259
Emergency Contact
+91 93139 48015
Address
Visit us anytime
F-90/1 , Okhla Industrial Area,
Phase -1 , New Delhi. India
Send us an email
medicanthealthcare@outlook.com
info@medicanthealthcare.com
Vestibulum luctus non mauris condimentum condimentum. Praesent quam augue, porta sit amet lacus at, tincidunt malesuada sem. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas.
Lorem ipsum dolor sit amet?
Pellentesque habitant morbi tristique?
Donec vitae libero fermentum?
Palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio) are drugs that block proteins in the cell called cyclin-dependent kinases (CDKs), particularly CDK4 and CDK6. Blocking these proteins in hormone receptor-positive breast cancer cells helps stop the cells from dividing. This can slow cancer growth.
On October 12,2021, the Food and Drug Administration approved abemaciclib (Verzenio,Eli Lilly and Company)with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score ≥20%, as determined by an FDA approved test. This is the first CDK 4/6 inhibitor approved for adjuvant treatment of breast cancer.